Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review... Purpose We conducted a systematic review and meta-analysis on survival impact of post-progression chemotherapy (post- Cx) after first-line chemotherapy (1st-Cx) and after second-line chemotherapy (2nd-Cx), and survival benefit of third-line chemotherapy (3rd-Cx) for advanced gastric cancer (AGC). Methods Phase III trials of systemic chemotherapy for AGC published in English between 2005 and 2015 or presented at annual meetings of ASCO or ESMO between 2013 and 2015 were searched. Numbers of patients, types of chemotherapy, patient baseline, proportion of patients receiving post-Cx (post-Cx%), median progression-free survival (mPFS), and median overall survival (mOS) of each treatment arm were surveyed; trials not reporting these parameters were excluded. Median post-progression survival (mPPS) was calculated as the difference between mOS and mPFS. Weighted Spearman’s cor - relation coefficients between post-Cx% and survival outcomes (mOS and mPPS) were calculated. The effect of post-Cx% on survival outcomes adjusted for the types of chemotherapy and patient characteristics was evaluated by meta-regression. Results Overall, 25 phase III trials of AGC were selected: 15 trials with 31 arms for 1st-Cx, and 10 trials with 16 arms for 2nd-Cx. Weighted Spearman’s correlation coefficients for post-Cx% and mOS/mPPS were 0.520/0.739 for 1st-Cx, and 0.767/0.823 for 2nd-Cx. Meta-regression analyses adjusting for types http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/survival-impact-of-post-progression-chemotherapy-in-advanced-gastric-pyMqij0oP1
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3569-9
Publisher site
See Article on Publisher Site

Abstract

Purpose We conducted a systematic review and meta-analysis on survival impact of post-progression chemotherapy (post- Cx) after first-line chemotherapy (1st-Cx) and after second-line chemotherapy (2nd-Cx), and survival benefit of third-line chemotherapy (3rd-Cx) for advanced gastric cancer (AGC). Methods Phase III trials of systemic chemotherapy for AGC published in English between 2005 and 2015 or presented at annual meetings of ASCO or ESMO between 2013 and 2015 were searched. Numbers of patients, types of chemotherapy, patient baseline, proportion of patients receiving post-Cx (post-Cx%), median progression-free survival (mPFS), and median overall survival (mOS) of each treatment arm were surveyed; trials not reporting these parameters were excluded. Median post-progression survival (mPPS) was calculated as the difference between mOS and mPFS. Weighted Spearman’s cor - relation coefficients between post-Cx% and survival outcomes (mOS and mPPS) were calculated. The effect of post-Cx% on survival outcomes adjusted for the types of chemotherapy and patient characteristics was evaluated by meta-regression. Results Overall, 25 phase III trials of AGC were selected: 15 trials with 31 arms for 1st-Cx, and 10 trials with 16 arms for 2nd-Cx. Weighted Spearman’s correlation coefficients for post-Cx% and mOS/mPPS were 0.520/0.739 for 1st-Cx, and 0.767/0.823 for 2nd-Cx. Meta-regression analyses adjusting for types

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: Mar 29, 2018

References

  • Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, J; Soerjomataram, I; Dikshit, R
  • Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    Wagner, AD; Grothe, W; Haerting, J; Kleber, G; Grothey, A; Fleig, WE
  • Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Thuss-Patience, PC; Kretzschmar, A; Bichev, D
  • Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
    Kang, JH; Lee, SI; Lim do, H
  • Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    Ford, HE; Marshall, A; Bridgewater, JA
  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Wilke, H; Muro, K; Cutsem, E
  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs, CS; Tomasek, J; Yong, CJ
  • Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
    Hironaka, S; Ueda, S; Yasui, H
  • Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
    Shitara, K; Matsuo, K; Muro, K; Doi, T; Ohtsu, A
  • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
    Shitara, K; Muro, K; Shimada, Y
  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, YK; Boku, N; Satoh, T
  • Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world
    Takashima, A; Iizumi, S; Boku, N
  • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    Cutsem, E; Moiseyenko, VM; Tjulandin, S
  • Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Al-Batran, SE; Hartmann, JT; Probst, S
  • S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Koizumi, W; Narahara, H; Hara, T
  • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Boku, N; Yamamoto, S; Fukuda, H
  • Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Ajani, JA; Rodriguez, W; Bodoky, G
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, YJ; Cutsem, E; Feyereislova, A
  • Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    Narahara, H; Iishi, H; Imamura, H
  • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
    Ohtsu, A; Shah, MA; Cutsem, E
  • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    Lordick, F; Kang, YK; Chung, HC
  • Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study
    Guimbaud, R; Louvet, C; Ries, P
  • Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
    Koizumi, W; Kim, YH; Fujii, M
  • Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
    Ochenduszko, S; Puskulluoglu, M; Konopka, K
  • Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
    Ryu, MH; Baba, E; Lee, KH
  • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
    Shen, L; Li, J; Xu, J
  • Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
    Yamada, Y; Higuchi, K; Nishikawa, K
  • Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study
    Ohtsu, A; Ajani, JA; Bai, YX
  • Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial)
    Higuchi, K; Tanabe, S; Shimada, K
  • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study
    Satoh, T; Xu, RH; Chung, HC
  • Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial
    Nishikawa, K; Fujitani, K; Inagaki, H
  • Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)
    Tanabe, K; Fujii, M; Nishikawa, K
  • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    Cunningham, D; Starling, N; Rao, S
  • Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
    Dank, M; Zaluski, J; Barone, C
  • Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Kang, YK; Kang, WK; Shin, DB
  • Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer
    Lee, KH; Hyun, MS; Kim, HK
  • Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)
    Shirao, K; Boku, N; Yamada, Y
  • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    Waddell, T; Chau, I; Cunningham, D
  • Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial
    Hecht, JR; Bang, Y-J; Qin, S; Chung, H-C; Xu, J-M; Park, JO
  • A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Xu, R-h; Sun, G-p; Lu, H-s; Peng, LY; Xu, J-m; Zhong, M-z
  • Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial
    Li, J; Qin, S; Xu, J
  • Untreated metastatic diffuse gastric adenocarcinoma (DGAC): randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial)
    Ajani, JA; Abramov, M; Bondar, V; Bondarenko, I; Shparyk, YV
  • Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
    Cunningham, D; Tebbutt, NC; Davidenko, I; Murad, AM; Al-Batran, S-E
  • First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis
    Hwang, IG; Lee, HR; Lee, HY; Ji, JH; Kang, JH; Lee, SI
  • A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36–0701)
    Nishikawa, K; Yoshino, S; Morita, S; Takahashi, T; Sakata, K; Nagao, J
  • Japanese gastric cancer treatment guidelines 2014 (ver. 4)